NCT01529593 2025-03-24
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
Clinical Trials
22 trialsNCT00838955 2024-07-10
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Loyola University
Phase 2 Terminated
NCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01378377 2018-07-30
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
EMD Serono
Phase 1 Terminated
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01264341 2017-02-14
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT01204450 2016-12-23
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00921310 2016-12-13
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 1/2 Terminated
NCT01061606 2016-11-09
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00996346 2015-09-01
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT01009203 2015-08-10
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01079767 2014-03-04
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT00887640 2014-02-26
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
Phase 2 Terminated
NCT00086840 2013-01-24
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00101088 2013-01-14
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00512668 2013-01-07
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01015664 2012-12-17
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Tennessee Cancer Institute
Phase 1/2 Terminated
NCT00593008 2011-12-02
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT00926107 2011-11-10
Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT00083993 2011-11-08
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Terminated